Dishman Seeks $25 Million For Newly Open China Production Facility
This article was originally published in PharmAsia News
Dishman Pharmaceuticals and Chemicals is offering its plant in China for sale even as it begins production of intermediates after years of regulatory delays.
You may also be interested in...
Join us for an audio catch-up on the latest major developments in the global biopharma industry, as reported by
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.